EQS-PVR

Disclosure of Shareholdings 23.06.2025, 07:00 Uhr von EQS News Jetzt kommentieren: 0

Werte zum Artikel
Name Aktuell Diff. Börse
BB Biotech 48,58 EUR ±0,00 % Lang & Schwarz

EQS Voting Rights Announcement: BB BIOTECH AG
Disclosure of Shareholdings

23.06.2025 / 07:00 CET/CEST
Dissemination of a Voting Rights Announcement transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.


Disclosure of Shareholdings

Submited, 18/06/2026

 

Notification ID: 77b1d1cb-63b3-4b8f-b0f1-bb767e0006e7

 

Disclosure notification concerning a single investor
Name of listed company

BB Biotech AG
 

PART 1: PERSON SUBJECT TO REPORTING OBLIGATION

Last name, first name, place of residence or company name and head office of the beneficial owner (art. 120 para. 1 FMIA) and/ or of the person who has the discretionary power to exercise the voting rights (art. 120 para. 3 FMIA):

Company: Saba Capital Management, L.P

City: New York

Country: United States of America (the)

 

PART 2: IN CASE OF INDIRECT PARTICIPATION

Last name, first name, place of residence or company name and head office of the person/s directly involved

 

PART 3: DATE AND REASON FOR THE REPORTING OBLIGATION

Date of the act that creates the obligation to notify: 17.06.2025

Facts and circumstances triggering the obligation to notify (art. 22 para. 1 b FMIO-FINMA):

Acquisition

Sale

Creation of a group

Change in group composition Termination of a group

Discretionary exercise of voting rights

Securities lending and comparable transactions

Exercise, non-exercise or expiration of derivative holdings

Granting (writing) of derivative holdings

Capital increase

Capital reduction

Ipso jure transfer or transfer due to a decision by a court or public authority

Change in the information subject to the obligation to notify

Other 


Total of voting rights below 3%

If the participation falls below the threshold of 3% (purchase positions and sale positions), no indication in Part 4 or Part 5 is required.

Total of voting rights <3%

 

PART 4: PURCHASE POSITIONS PURSUANT TO ART. 14 PARA. 1 A FMIO-FINMA

 

Total of all purchase positions:

Total of all equity securities or equity related securities (item 1), number of voting rights that can be exercised at one’s own discretion (item 3) and derivative holdings (item 4)

Number of voting rights Percentage
S1 = [1.1] + [3.1] + [4.1] S2 = [1.2] + [3.2] + [4.2]
1,697,636 3.064%

 

Basis of calculation (art. 14 para. 2 FMIO-FINMA): total number of voting rights pursuant to the entry in the commercial register (see Central Business Names Index) or Publication according to art. 115 para. 3 FMIO:

 55,400,000 
 

  1. Equity securities or equity related securities
 
Shares Number Voting rights1
    Number Percentage2
Registered share 503,638 503,638 0.909%
 
Total
  [1.1]
503,638
[1.2]
0.909%
  1. Whether exercisable or not
  2. Calculated on the basis of the total number of voting rights pursuant to the entry in the commercial register (art. 14 para. 2 FMIO-FINMA)

 

  1. Securities lending and comparable transactions in equity securities

Of the equity securities mentioned in item 1 above, the following part is held due to securities lending and comparable transactions (art. 17 FMIO-FINMA):

 

 
 
Shares
 
 
Number
 
 
Proportion of voting rights
 
Nature of the
legal transaction
Agreed date of return transfer or, if there is a right to choose, whether this applies to the contracting party subject to the obligation to notify or to
the counterparty

 

  1. Voting rights that can be exercised at one's own discretion

The following voting rights were delegated by a third party and can be exercised at one's own discretion.

 

Voting rights

Is the person who has full discretionary powers to exercise voting rights directly or indirectly controlled?

Yes  No

 
  1. Derivative holdings

Conversion and share purchase rights (such as call-options according to art. 15 para. 2 a FMIO-FINMA), granted (written) share sale rights and other derivative holdings:

 

Type of rights Number of rights Number of voting rights conferred Security ID number (ISIN) if available or basic terms
    Number Percentage2 Identity of issuer, subscription ratio, exercise price,
exercise period, exercise type
CFD 1,193,998 1,193,998 2.155% CH0038389992
 
    [4.1]  [4.2]  
Total   1,193,998 2.155%  

2 Calculated on the basis of the total number of voting rights pursuant to the entry in the commercial register (art. 14 para. 2 FMIO-FINMA)

 

  1. Securities lending and comparable transactions in derivative holdings

Of the derivative holdings mentioned in item 4 above, the following part is held due to securities lending and comparable transactions (art. 17 FMIO-FINMA):

 

 
 
Nature of the legal transaction
 
 
Number of rights
 
Number of reported voting
rights
 
 
Proportion of voting rights
Agreed date of return transfer or, if there is a right to choose, whether this applies to the contracting party subject to the obligation to notify or to
the counterparty


PART 5: SALE POSITIONS PURSUANT TO ART. 14 PARA. 1 B FMIO-FINMA

Total of all sale positions: 
Basis of calculation (art. 14 para. 2 FMIO-FINMA): total number of voting rights pursuant to the entry in the commercial register (see Central Business Names Index) or Publication according to art. 115 para. 3 FMIO:

 55,400,000 

 

Derivative holdings

Share sale rights (such as put-options according to art. 15 para. 2 a FMIO-FINMA), granted (written) conversion and share purchase rights and other derivative holdings:

 

Type of rights Number of rights Number of voting rights conferred Security ID number (ISIN) if available or basic terms
    Number Percentage2 Identity of issuer, subscription ratio, exercise price,
exercise period, exercise type

Total

2 Calculated on the basis of the total number of voting rights pursuant to the entry in the commercial register (art. 14 para. 2 FMIO-FINMA)



23.06.2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: BB BIOTECH AG
Schwertstrasse 6
8200 Schaffhausen
Switzerland
Internet: www.bbbiotech.ch

 
End of News EQS News Service

2158408  23.06.2025 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Werbung
Weiter abwärts?
Kurzfristig positionieren
Ask: 0,80
Hebel: 6
mit moderatem Hebel
Smartbroker
Morgan Stanley
Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie hier: MM96YR. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
News-Kommentare
Thema
1 Söder sieht Deutschland so stark unter Druck wie noch nie Hauptdiskussion
2 ROUNDUP/Merkel: 'Die Pandemie war eine demokratische Zumutung' Hauptdiskussion
3 Nach Reformen: Argentinien kehrt an den Finanzmarkt zurück Hauptdiskussion
4 ROUNDUP: Linke ebnet Weg zur Verabschiedung des Rentenpakets Hauptdiskussion
5 EU einig über Komplettverzicht auf Gas aus Russland Hauptdiskussion
6 Moskau erklärt Pokrowsk für erobert Hauptdiskussion
7 Trump hat sich für neuen Fed-Chef entschieden Hauptdiskussion
Alle Diskussionen
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer